8-K: Arcadia Biosciences Appoints Interim CFO, Advances Merger

Arcadia Biosciences announced the resignation of CFO Mark Kawakami, the appointment of CEO Thomas J. Schaefer as interim CFO, and provided an update on its all-stock merger with Roosevelt Resources.

Summary

• Mark Kawakami, Chief Financial Officer and Principal Accounting Officer, notified Arcadia Biosciences of his resignation, effective September 12, 2025.
• Mr. Kawakami's resignation was not due to any disagreement with the Company or its auditors regarding operations, policies, financial statements, or accounting practices.
• Thomas J. Schaefer, current President and Chief Executive Officer, was appointed Interim Chief Financial Officer and Principal Accounting Officer, effective upon Mr. Kawakami's resignation.
• Mr. Schaefer previously served as CFO from January 2023 until his appointment as President and CEO in July 2024.
• No change to Mr. Schaefer's compensation was made in connection with his interim CFO appointment.
• Arcadia Biosciences is proceeding with an all-stock transaction to combine with Roosevelt Resources, LP, as per a Securities Exchange Agreement entered into on December 4, 2024.
• Arcadia will issue shares of its common stock to Roosevelt partners in exchange for all of Roosevelt's equity interests.
• A Registration Statement on Form S-4 (File no. 333-284972) was filed with the SEC on February 14, 2025, and amended on July 31, 2025, related to the proposed transaction.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a CFO resignation can be a concern, the filing explicitly states no disagreements, and the appointment of the CEO with prior CFO experience as interim provides continuity. The merger update confirms ongoing strategic progress, which is generally positive.

Positives

• The transition of the Chief Financial Officer role appears to be managed smoothly, with the outgoing CFO offering advisory assistance.
• The appointment of Thomas J. Schaefer as Interim CFO leverages his prior experience in the role (January 2023 to July 2024), ensuring continuity and familiarity with the company's finances.
• The ongoing progress of the all-stock merger with Roosevelt Resources, LP, indicates strategic execution towards combining the companies.

Negatives

• The resignation of a Chief Financial Officer, even if amicable, can introduce a degree of uncertainty regarding financial leadership, particularly during a significant corporate transaction like a merger.

Risks

• Risks associated with the proposed all-stock transaction with Roosevelt Resources, LP, as detailed in the Registration Statement on Form S-4, which investors are urged to review.

Future Outlook

Arcadia Biosciences anticipates mailing a definitive proxy statement/prospectus to stockholders after the Registration Statement on Form S-4 is declared effective by the SEC. This will facilitate a stockholder meeting to consider matters related to the proposed all-stock transaction with Roosevelt Resources, LP, moving towards the combination of the two companies.

Management Comments

• Mr. Kawakami indicated that he would be available, upon the Company's request, to provide assistance as an advisor or consultant after his departure as an employee.

Industry Context

The all-stock transaction with Roosevelt Resources, LP, represents a strategic move for Arcadia Biosciences, aligning with broader industry trends of consolidation and expansion through mergers and acquisitions to enhance market position or diversify offerings. The management changes, while internal, are part of ensuring leadership stability during such strategic transitions.

Management Changes

Stakeholder Impact

• Shareholders: Will be required to vote on matters related to the proposed merger with Roosevelt Resources, LP, and will receive shares in the combined entity.
• Employees: Management changes at the CFO level may impact internal financial operations and reporting structures.
• Investors: Provided with updates on key management personnel and the progress of a significant strategic transaction, influencing investment decisions.

Next Steps

• SEC to declare the Registration Statement on Form S-4 effective.
• Arcadia to mail a definitive proxy statement/prospectus to its stockholders.
• Hold a meeting of stockholders to consider matters relating to the proposed transaction.
• Closing of the all-stock transaction with Roosevelt Resources, LP.

Key Dates

Recommendation

The filing provides updates on a management change and the procedural progress of a previously announced merger. There are no new financial results or significant operational shifts that would warrant a change in investment thesis. The interim CFO appointment leverages existing leadership, and the merger is proceeding as expected. Investors should hold and await further details, particularly the definitive proxy statement/prospectus, for a more comprehensive understanding of the merger's implications.

Keywords

Arcadia Biosciences, RKDA, CFO resignation, Interim CFO, Thomas J. Schaefer, Mark Kawakami, Roosevelt Resources, Merger, All-stock transaction, SEC filing, Corporate governance, Nasdaq